FDA – Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products (Catapult’s regulatory round-up – March)
The Centre for Biologics Evaluation and Research (CBER) has issued a draft guidance to receive comments on revised recommendations for evaluating donor eligibility using individual risk-based questions. This draft guidance, when finalized will provide blood establishments that collect blood or blood components, including Source Plasma, with FDA’s revised donor deferral recommendations for individuals with increased risk for transmitting human immunodeficiency virus (HIV) infection.
Published on the 3rd of April 2023 in Catapult’s March regulatory round-up.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (19 février 2024). FDA – Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products (Catapult’s regulatory round-up – March). ELSIBI. Consulté le 19 janvier 2025 à l’adresse https://doi.org/10.58079/vv4z
